Answers are grounded in this paper and cite their sources.
To analyze the eligibility of acetylcholine receptor antibody-positive generalized myasthenia gravis (AchR+ gMG) patients treated in routine care into the phase III clinical trial of newly approved complement and FCRN inhibitor therapies.
No takes yet. Share an insight, caveat, or question.
Katyal et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: